CervoMed (CRVO) Earnings Analysis
CervoMed (CRVO) next reports earnings on 2026-08-14, consensus EPS -0.79857 USD. Last quarter (2026-05-18) it beat with EPS -0.86 USD vs -0.9 USD est (+4.4%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -0.85.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRVO next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | -0.79857 USD |
| Revenue estimate | 0.00B |
CRVO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-18 | -0.86 USD | -0.9 USD | +4.4% | Beat |
| 2026-03-13 | -0.88 USD | -0.79 USD | -11.4% | Miss |
| 2025-11-07 | -0.84 USD | -0.68 USD | -23.5% | Miss |
| 2025-08-08 | -0.7 USD | -0.61473 USD | -13.9% | Miss |
| 2025-05-12 | -0.56 USD | -0.6 USD | +6.7% | Beat |
| 2025-03-17 | -0.8 USD | -0.67 USD | -19.4% | Miss |
| 2024-08-09 | -0.27 USD | -0.306 USD | +11.8% | Beat |
Beat rate: 3/7 (43%) over reported quarters with consensus data.
CRVO valuation and analyst view
| Trailing P/E | -0.85 |
|---|---|
| Trailing EPS | -3.24427 USD |
| Price / book | 2.42 |
| Dividend yield | 0.00% |
| Market cap | 0.03B |
| Analyst consensus | Buy (7 buy / 0 hold / 0 sell) |
| Avg price target | 9 USD |
Related research pages
Frequently asked questions
When is CervoMed (CRVO)'s next earnings date?
CervoMed is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.79857 USD and revenue estimate of 0.00B.
Did CRVO beat earnings last quarter?
In its 2026-05-18 report, CRVO posted EPS of -0.86 USD versus a -0.9 USD estimate — a beat of 4.4%.
What is CRVO's earnings track record?
Over the last 7 reported quarters with consensus data, CRVO beat estimates 3 times (43%).
What is CRVO's current P/E ratio and EPS?
CRVO trades at a trailing P/E of -0.85 on trailing EPS of -3.2442703691674484 USD.
What do analysts rate CRVO?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 9 USD.